Adrenalectomy Improves Diabetes in A-ZIP/F-1 Lipoatrophic Mice by Increasing Both Liver and Muscle Insulin Sensitivity

Martin Haluzik,1 Kelly R. Dietz,1 Jason K. Kim,2 Bernice Marcus-Samuels,1 Gerald I. Shulman,2 Oksana Gavrilova,1 and Marc L. Reitman1

The virtually fatless A-ZIP/F-1 mouse is profoundly insulin resistant, diabetic, and a good model for humans with severe generalized lipoatrophy. Like a number of other mouse models of diabetes, the A-ZIP/F-1 mouse has elevated serum corticosterone levels. Leptin infusion lowers the corticosterone levels, suggesting that leptin deficiency contributes to the hypercorticosteronemic state. To test the hypothesis that the increased glucocorticoids contribute to the diabetes and insulin resistance, we examined the effect of adrenalectomy on A-ZIP/F-1 mice. Adrenalectomy significantly decreased the blood glucose, serum insulin, and glycated hemoglobin levels. Hyperinsulinemic-euglycemic clamps were performed to characterize the changes in whole-body and tissue insulin sensitivity. The adrenalectomized A-ZIP/F-1 mice displayed a marked improvement in insulin sensitivity in both muscle and liver.

To understand the physiological roles of adipose tissue, we studied the A-ZIP/F-1 transgenic mouse, which has virtually no white adipose tissue and a significantly reduced amount of brown adipose tissue (1). These mice express a dominant-negative protein in adipose tissue that heterodimerizes with and inactivates members of the CCAAT/enhancer binding protein (C/EBP) and Jun families of basic leucine zipper transcription factors. The A-ZIP/F-1 phenotype closely resembles that of humans with severe lipoatrophic diabetes (2,3). Features of the phenotype include hyperglycemia, hyperinsulinemia, hypoleptinemia, hepatic steatosis, and increased serum triglyceride, fatty acid, and corticosterone levels (1,4,5). Reconstitution of adipose tissue by transplantation demonstrated that the lack of adipose tissue causes the metabolic phenotype (6). Leptin can increase insulin sensitivity (7,8), and leptin deficiency is a significant contributor to the etiology of the phenotype (9,10; C. Colombo and M.L.R., unpublished observations).

Glucocorticoids are crucial factors in the regulation of food intake and body adiposity (11,12), affecting energy metabolism at both the central and peripheral levels (13,14). In the central nervous system, glucocorticoids increase food intake and energy expenditure through multiple mechanisms, including stimulation of the hypothalamic neuropeptide Y pathway (15,16) and inhibition of corticotrophin-releasing factor/urocortin and norepinephrine pathways (17,18). In the periphery, glucocorticoids have many actions on lipid and carbohydrate metabolic pathways, usually antagonizing insulin effects. They stimulate hepatic gluconeogenesis by increasing activities of the crucial enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (19). In addition, glucocorticoids provide gluconeogenic substrates by increasing the release of amino acids from muscle and glycerol from fat and they also have a permissive action on glucagon- and epinephrine-stimulated gluconeogenesis (20). Glucocorticoids directly inhibit insulin secretion from pancreatic β-cells (21) and blunt glucose uptake in peripheral tissues through glucose transporter translocation from the plasma membrane to intracellular sites (22).

Increased glucocorticoid levels contribute to hyperphagia and insulin resistance in some rodent models of obesity, including leptin-deficient ob/ob, leptin receptor–deficient db/db, and agouti-overexpressing Aγ/a mice (23–26). In these models, adrenalectomy reduces food intake and blood glucose and insulin levels, ameliorating the obesity and insulin resistance.

To clarify the contribution of the increased corticosterone levels to the A-ZIP/F-1 phenotype, we examined the effect of adrenalectomy. We demonstrate here that adrenalectomy significantly attenuates the diabetes and insulin resistance of the A-ZIP/F-1 mice, and that this occurs by increasing insulin sensitivity in both liver and skeletal muscle.

RESEARCH DESIGN AND METHODS

Animals. A-ZIP/F-1 mice hemizygous for the transgene on the FVB/N background were studied along with wild-type littermates. The mice were main-
tained on a 12-h light/dark cycle (lights on 0600 to 1800). Pellet diet (NIH-07, 12.9 kcal % fat) and drinking water were provided ad libitum. After adrenalectomy or sham operation, mice received 0.9% NaCl instead of water. Animal experiments were approved by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Animal Care and Use Committee.

Surgery and animal handling. Operations were carried out under ketamine (100 mg/kg; Fort Dodge Animal Health, Fort Dodge, IA) and xylazine (10 mg/kg; Phoenix Scientific, St Joseph, MO) anesthesia. Adrenalectomy was performed by bilateral flank incision. Control animals underwent sham operations, in which the adrenal glands were grasped but not removed. Catheter insertion (procedure adapted from MacLeod and Shapiro [27]) was carried out 7–9 days after the first (adrenalectomy or sham) operation. Adrenalectomized mice were given one dose of hydrocortisone (4 mg/kg body wt i.p. in 0.9% saline; Sigma, St. Louis, MO) 2 h before anesthesia for catheter insertion. The silastic catheter (inner diameter 0.30 mm, outer diameter 0.64 mm, no. 508-001; Dow Corning, Midland, MI), filled with heparin solution (100 USP units/ml in 0.9% NaCl), was inserted via a right lateral neck incision, advanced into the superior vena cava via the right internal jugular vein, and sutured in place. The distal end of the catheter was knotted, tunneled subcutaneously, exteriorized first at the dorsal cervical midline, and then further tunneled subcutaneously and exteriorized in the dorsal midline, 2 cm above the tail. A silk suture was fastened around the catheter at the neck site. On the day of the clamp, the catheter was externalized by pulling the suture through the dorsal cervical incision site.

Hyperinsulinemic-euglycemic clamp. The clamps were performed as described by Kim et al. (28) using [3-3H]glucose and 2-deoxy-D-[1-14C] glucose (both from NEN Life Science Products, Boston, MA) for the estimation of whole-body glucose fluxes and tissue glucose uptake, respectively. In vivo glucose flux analysis. The determination of plasma [3-3H]glucose and 2-deoxy-D-[1-14C] glucose concentrations and tissue 2-deoxy-D-[1-14C] glucose-6-phosphate was performed as described previously (28).

Calculations. Basal endogenous glucose production was calculated as the ratio of the preclamp [3-3H]glucose infusion rate (dpm/min) to the specific activity of the plasma glucose (mean of the 90- to 120-min values in dpm/μmol). Clamp whole-body glucose uptake was calculated as the ratio of the [3-3H]glucose infusion rate (dpm/min) to the specific activity of plasma glucose (dpm/μmol) during the last 20 min of the clamp (mean of the 100- to 120-min samples). Whole-body glycolysis was determined from the rate of increase in plasma 3H2O determined by linear regression using the 80- to 120-min points. Plasma 3H2O concentrations were measured from the difference between nondried versus dried plasma 3H counts. Clamp endogenous glucose production was determined by subtracting the average glucose infusion rate in the last 20 min of clamp from the whole-body glucose uptake. Whole-body glycogen and lipid synthesis were estimated by subtracting the whole-body glycolysis from the whole-body glucose uptake, which assumes that glycolysis and glycogen/lipid synthesis account for the majority of insulin-stimulated glucose uptake (29). Muscle glucose uptake was calculated from the plasma 2-deoxy-D-[1-14C] glucose concentration profile (using plasma 14C counts at 80–120 min, the area under the curve was calculated by trapezoidal approximation) and tissue 2-deoxy-D-[1-14C] glucose-6-phosphate content as described previously (30). Skeletal muscle glycogen synthesis was calculated from the 3H incorporation to muscle glycogen as described (30). Skeletal muscle glycolysis was estimated by subtracting the skeletal muscle glycogen synthesis from the skeletal muscle glucose uptake.

Biochemical and hormonal assays. Glucose was measured using a Glucometer Elite (Bayer, Elkhart, IN). Insulin (no. SRI-13K, Linco Research, St Charles, MO), corticosterone (no. 07-120102; ICN Biomedicals, Costa Mesa, CA), triglycerides (no. 337-B; Sigma), nonesterified fatty acids (no. 13831175; Roche Molecular Biochemicals), and glycated hemoglobin (no. 442-B; Sigma) were measured with the indicated kits. Liver triglycerides were measured by solvent extraction followed by a colorimetric assay (31).

RNA analysis. Total RNA extraction and Northern blots were done as previously described, using probes excised from plasmids (32,33).

Statistical analysis. Data are expressed as means ± SE. Statistical significance between the groups was determined with SigmaStat (SPSS, Chicago, IL) using Student’s t test or two-way ANOVA.

RESULTS
Leptin treatment reverses the hypercorticosteronemia of fed A-ZIP/F-1 mice. A-ZIP/F-1 mice have increased corticosterone levels as compared with wild-type littersmates (4). The average corticosterone level in fed A-ZIP/F-1 mice was sevenfold higher than in wild-type controls (Fig. 1). In fasted mice, the difference between
TABLE 1
Effect of adrenalectomy in female mice.

<table>
<thead>
<tr>
<th></th>
<th>Wild type</th>
<th>A-ZIP/F-1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sham</td>
<td>Adrenalectomy</td>
</tr>
<tr>
<td>Body weight, 8 weeks (g)</td>
<td>22.9 ± 0.8</td>
<td>23.4 ± 0.6</td>
</tr>
<tr>
<td>Body weight, 10 weeks (g)</td>
<td>23.4 ± 0.2</td>
<td>24.2 ± 0.3</td>
</tr>
<tr>
<td>Blood glucose (mg/dl)</td>
<td>149 ± 7</td>
<td>128 ± 4*</td>
</tr>
<tr>
<td>Insulin (ng/ml)</td>
<td>1.13 ± 0.04</td>
<td>0.84 ± 0.03*</td>
</tr>
<tr>
<td>Glycated hemoglobin (%)</td>
<td>7.4 ± 2.7</td>
<td>6.6 ± 2.6</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>137 ± 6</td>
<td>147 ± 4</td>
</tr>
<tr>
<td>Fatty acids (µmol/l)</td>
<td>210 ± 8</td>
<td>221 ± 19</td>
</tr>
<tr>
<td>Corticosterone (ng/ml)</td>
<td>113 ± 12</td>
<td>34 ± 2*</td>
</tr>
<tr>
<td>Liver weight (g)</td>
<td>1.21 ± 0.04</td>
<td>1.33 ± 0.03</td>
</tr>
<tr>
<td>Liver triglycerides (µmol/g tissue)</td>
<td>2.43 ± 0.39</td>
<td>2.96 ± 0.38</td>
</tr>
<tr>
<td>Food intake (g/mouse/day)</td>
<td>3.50 ± 0.40</td>
<td>3.37 ± 0.14</td>
</tr>
</tbody>
</table>

Adrenalectomy was performed at 8 weeks and mice were studied at 10 weeks. Mice were bled in the morning in the nonfasted state. Food intake was measured in individually housed mice 7–11 days after adrenalectomy. Data are means ± SE; n = 6 per group. *P < 0.05 vs. sham group of the same genotype; †P < 0.05 vs. wild-type sham.

Adrenal axis, so the effects of leptin on the corticosterone levels were studied. Leptin treatment for 6 days reduced the corticosterone levels of fed A-ZIP/F-1 mice (P = 0.06), but did not change the levels in fasting mice. Efficacy of leptin treatment was established by the increase in serum leptin levels and, in A-ZIP/F-1 mice, reduction in food intake, glucose, and insulin levels (Fig. 1). These results suggest that leptin deficiency contributes to the hypercorticosteronemia of the A-ZIP/F-1 mice.

Adrenalectomy attenuates the diabetes of A-ZIP/F-1 mice. Adrenalectomy was used to study the contribution of the hypercorticosteronemia to the phenotype of the A-ZIP/F-1 mice. In the first study, the blood chemistry and anatomy of female mice 10 weeks old and 2 weeks post-adrenalectomy were examined in the nonfasted state. The sham-operated A-ZIP/F-1 had elevated blood glucose (4-fold), insulin (3-fold), insulin (2-fold), triacylglycerol (5-fold), fatty acid (3-fold), and corticosterone (3-fold) levels, as compared with sham-operated wild-type littermates (Table 1), confirming previous data (1). The weight and triglyceride content of A-ZIP/F-1 livers were also markedly increased, as was body weight, albeit to a lesser degree (Table 1). Adrenalectomy of the A-ZIP/F-1 mice significantly lowered blood glucose, serum insulin, and glycated hemoglobin levels as compared with the sham-operated controls (Table 1). However, these parameters remained higher than in wild-type mice. A tendency (which did not reach statistical significance) toward lower serum triglycerides and fatty acid levels was also observed in adrenalectomized A-ZIP/F-1 mice. Adrenalectomy increased body weight of A-ZIP/F-1 mice as compared with sham-operated A-ZIP/F-1 group despite decreased food intake. A-ZIP/F-1 liver weight was not changed by adrenalectomy.

In wild-type mice, adrenalectomy also decreased insulin and glucose levels, but the changes were modest in magnitude. No effect of adrenalectomy on glycated hemoglobin, triglycerides, fatty acids, food intake, and body or liver weight was observed in wild-type mice (Table 1). Adrenalectomy efficacy was confirmed by the reduction in serum corticosterone levels. Taken together, these data demonstrate that reversal of the hypercorticosteronemia by adrenalectomy greatly improves the diabetes and tends to improve the hyperlipidemia of the A-ZIP/F-1 mice.

Adrenalectomized mice have decreased plasma glucose and basal endogenous glucose production after 12 h of fasting. We next performed hyperinsulinemic-euglycemic clamps to elucidate the mechanisms by which adrenalectomy improved the diabetes of A-ZIP/F-1 mice. At the beginning of the clamps (after 12 h of fasting) both wild-type and A-ZIP/F-1 adrenalectomized groups had lower plasma glucose and insulin levels than the sham-operated controls (Table 2). In addition, some adrenalectomized mice (both wild type and A-ZIP/F-1) had decreased body temperature after 12 h of fasting. Basal endogenous glucose production was greatly reduced in both adrenalectomized groups as compared with sham-operated animals (Fig. 2), suggesting that decreased basal endogenous glucose production contributes to the lower basal glucose values.

TABLE 2
Metabolic parameters during basal (12-h fasted) period and hyperinsulinemic-euglycemic clamp in the sham-operated and adrenalectomized wild-type and A-ZIP/F-1 female mice.

<table>
<thead>
<tr>
<th></th>
<th>Wild type</th>
<th>A-ZIP/F-1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sham</td>
<td>Adrenalectomy</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>21.6 ± 0.6</td>
<td>22.8 ± 0.8</td>
</tr>
<tr>
<td>Basal plasma glucose (mg/dl)</td>
<td>137 ± 13</td>
<td>76 ± 12*</td>
</tr>
<tr>
<td>Basal plasma insulin (ng/ml)</td>
<td>0.96 ± 0.09</td>
<td>0.47 ± 0.11*</td>
</tr>
<tr>
<td>Clamp plasma glucose (mg/dl)</td>
<td>110 ± 7</td>
<td>114 ± 3</td>
</tr>
<tr>
<td>Clamp plasma insulin (ng/ml)</td>
<td>3.6 ± 0.4</td>
<td>3.5 ± 0.7</td>
</tr>
<tr>
<td>Corticosterone (ng/ml)</td>
<td>101 ± 22</td>
<td>15 ± 5*</td>
</tr>
</tbody>
</table>

Values are means ± SE; n = 6 per group. *P < 0.05 vs. sham group of the same genotype; †P < 0.05 vs. wild-type sham.
Under the hyperinsulinemic clamp conditions, the sham-operated A-ZIP/F-1 mice had decreased whole-body glucose uptake and whole-body glycolysis as compared with wild-type controls (Fig. 3), confirming previous results (5). The difference in whole-body glycogen and lipid synthesis between sham-operated A-ZIP/F-1 and wild-type group was of borderline statistical significance (P = 0.054). Whole-body glucose uptake and whole-body glycolysis were higher in adrenalectomized as compared with sham-operated A-ZIP/F-1 mice while no difference was found between adrenalectomized versus sham-operated wild-type mice (Fig. 3). The reduction in serum corticosterone levels confirmed the technical adequacy of the adrenalectomies (Table 2).

Adrenalectomy increases liver insulin sensitivity in both A-ZIP/F-1 and wild-type mice. In A-ZIP/F-1 mice, the clamp glucose infusion rate was significantly higher in adrenalectomized as compared with sham-operated controls (Fig. 3). Thus, clamp endogenous glucose production (the difference between whole-body glucose uptake) was lower in adrenalectomized mice (Fig. 2). As noted above, the basal endogenous glucose production was reduced in adrenalectomized A-ZIP/F-1 mice, but this was further reduced during the clamp (Fig. 2). Thus the pronounced effect of adrenalectomy to sensitize endogenous glucose production to suppression by insulin was observed in both wild-type and A-ZIP/F-1 mice.

As glucocorticoids are important stimulators of gluconeogenesis, the mRNA levels of two gluconeogenic enzymes, PEPCK and glucose-6-phosphatase, were measured. Liver PEPCK and glucose-6-phosphatase mRNA levels did not differ between sham-operated wild-type and A-ZIP/F-1 mice (Fig. 4). However, the PEPCK mRNA expression in adrenalectomized A-ZIP/F-1 and wild-type mice was significantly lower, while the changes in glucose-6-phosphatase mRNA did not reach statistical significance (Fig. 4).

Adrenalectomy increases muscle insulin sensitivity in A-ZIP/F-1 mice. Gastrocnemius muscle glucose uptake was higher in adrenalectomized A-ZIP/F-1 mice than in sham-operated A-ZIP/F-1 mice, but was still lower than in sham-operated wild-type mice (Fig. 5). The rate of gastrocnemius glycogen synthesis was completely normalized in adrenalectomized A-ZIP/F-1 mice. No significant difference...
Glucocorticoids play a pivotal role in the regulation of whole-body fuel homeostasis. Chronic glucocorticoid excess causes increased food intake, visceral obesity, and insulin resistance, while the lack of glucocorticoids decreases food intake, body adiposity, and circulating glucose and insulin levels. The effects of glucocorticoids are documented; however, to our knowledge, no in vivo glucose clamp studies directly exploring the influence of adrenalectomy on glucose homeostasis have been performed previously. We demonstrate that adrenalectomy in wild-type mice produces a profound drop in basal endogenous glucose production and greatly sensitizes the liver to insulin-induced suppression of endogenous glucose production. Although glucocorticoid excess is known to induce insulin resistance and adrenalectomy might be expected to increase muscle insulin sensitivity, no changes in muscle glucose uptake were observed in adrenalectomized wild-type mice.

We showed previously that suppression of endogenous glucose production during a hyperinsulinemic clamp is significantly blunted in A-ZIP/F-1 mice, indicating liver insulin resistance (5). Glucocorticoids contribute importantly to regulation of hepatic glucose production by stimulating gluconeogenic enzymes PEPCK and glucose-6-phosphatase. Adrenalectomy markedly decreased endogenous glucose production in both A-ZIP/F-1 and wild-type mice in part by reduced liver PEPCK expression. The improvement caused by adrenalectomy may be due to reversal of the hypercorticosteronemic state, to creation of a hypocorticosteronemic state, or both.

It should be noted that the beneficial effect of adrenalectomy in A-ZIP/F-1 mice might not reflect a selective reversal of lipoatrophic pathology, but rather a second insult that nonspecifically ameliorates their diabetes.

Glucocorticoid excess contributes to muscle insulin resistance in A-ZIP/F-1 mice. In humans, cortisol excess decreases whole-body (chiefly muscle) glucose uptake (35,36). Glucocorticoids reduce muscle glucose uptake by decreasing GLUT4 translocation to the cell surface (22,37,38). Insulin-stimulated muscle glucose uptake in adrenalectomized A-ZIP/F-1 mice was nearly doubled as compared with A-ZIP/F-1 controls, but was still less than that in wild-type mice. Muscle glycogen synthesis in A-ZIP/F-1 mice was normalized by adrenalectomy. No such changes were observed in adrenalectomized wild-type mice. Possibly, the effects of glucocorticoids on muscle glucose uptake can be observed only by comparing elevated with normal or low levels and not by comparing normal with low glucocorticoid levels.

Adrenalectomy reduced food intake in the A-ZIP/F-1 mice. However, the improvement in insulin resistance is not simply due to reduced food intake, since pair feeding A-ZIP/F-1 mice or aP2-SREBP-1c lipoatrophic mice to wild-type levels does not significantly reduce the severity of the diabetes (39,9; O.G. and M.L.R., unpublished observations). Tissue-specific ablation of the glucocorticoid receptor gene (40) should allow identification of the relevant sites of glucocorticoid action. It should also be noted that some obese models (such as melanocortin receptor-4 knockout [41] and syndecan-1–overexpressing [42] mice) and most models of human obesity do not appear to have high systemic glucocorticoid levels. It was recently demonstrated that increased local corticosterone production in adipose tissue by transgenic overexpression of 11β-hydroxysteroid dehydrogenase type-1 in fat induces visceral obesity with insulin resistance and diabetes without changing systemic corticosterone levels (43).

What causes the chronic hypercorticosteronemia of the A-ZIP/F-1 mice? One contributor is leptin deficiency, which increases signaling by hypothalamic CRH (corticotropin releasing hormone) neurons, stimulating pituitary ACTH (adrenocorticotropic hormone) release, and thus increasing adrenal glucocorticoid production (44–46). This mechanism could explain the hypothalamic-pituitary-adrenocortical axis response to starvation. Leptin treatment of A-ZIP/F-1 mice normalized fed but not fasting corticosterone levels, suggesting that the high-fed corticosterone levels are the result of severe leptin deficiency, while the fasting levels have multiple causes. Reduction of corticosterone levels may be one of the mechanisms by which leptin treatment improves glucose and insulin levels in A-ZIP/F-1 mice.

In conclusion, the chronically increased corticosterone levels contribute to the diabetes and insulin resistance of the A-ZIP/F-1 mice. Adrenalectomy relieves the glucocorticoid excess and improves insulin sensitivity in liver and skeletal muscle.

**DISCUSSION**

**FIG. 5.** Muscle (gastrocnemius) glucose uptake and muscle glycogen synthesis in female sham-operated (black bars) and adrenalectomized (white bars) wild-type and A-ZIP/F-1 mice. Values are means ± SE; n = 6/group. *P < 0.05 vs. sham group of the same genotype; +P < 0.05 for A-ZIP/F-1 groups vs. wild-type sham group.
ACKNOWLEDGMENTS

This study was supported by intramural NIDDK funds and R01 DK-40936 and U24 DK-59635.

We thank Dr. P. Gorden for helpful comments on the manuscript.

REFERENCES


